View in EDS HTML Full Text PDF Full Text

BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.

Saved in:
Bibliographic Details
Title: BCR kinase inhibitors, idelalisib and ibrutinib, are active and effective in Richter syndrome.
Authors: Visentin, Andrea1,2, Imbergamo, Silvia1, Scomazzon, Edoardo1, Pravato, Stefano1, Frezzato, Federica1,2, Bonaldi, Laura3, Pizzi, Marco4, Vio, Stefania5, Gregianin, Michele6, Burei, Marta7, Facco, Monica1,2, Semenzato, Gianpietro1,2, Piazza, Francesco1,2, Trentin, Livio1,2, livio.trentin@unipd.it
Source: Angewandte Chemie; Apr2019, Vol. 131 Issue 15, p193-197, 5p
Database: Applied Science & Technology Source
Full text is not displayed to guests.
Description
ISSN:00448249
DOI:10.1111/bjh.15440